More Major Options Gainers

More New Highs Options 

When we updated readers on our bitcoin related options plays yesterday morning, we had already witnessed gains in the neighborhood of 200%  We made sure to caution our readers that we expected to see further gains in all targets based on the surging price of bitcoin, which has now surpassed $38K/BTC.

Our expectations were met to the letter, as the following new highs were tacked on. Here are the total possible gains that were on the table following our signaling of these targets:

RIOT Weekly $17-19 Calls 
$17: .65-2.75 (+323%)
$18: .52-2.96 (+469%)
$19: .35-2.20 (+529%)
______

MARA 01/15 $11-12 Calls
$11: 1.32-6.69 (+407%)
$12: 1.06-5.81 (+448%)
______

MARA 01/15 $13-15 Calls
$13
: .80-5.00 (+525%)
$14: .62-4.27 (+589%)
$15: .50-3.65 (+630%)

Once again today, we feel as if more new highs are on the way for these contract sets, but we also want to stay at the money with our potential strikes, so we are going to add the MARA 01/15 $20 Calls and the RIOT Weekly $20-21 Calls.


Cannabis Plays Coming Back 

With the democrats winning control of the US senate in the GA runoffs, the odds of finally seeing marijuana reclassified at the federal level sooner rather than later, have now gone up considerably. Thus we would like to signal a couple of ideas related to the cannabis space, and will likely be more focused on related stock and options ideas going forward.

CGC Weekly $31-31.50 Calls
TLRY Weekly $11.50-12 Calls 


More Fresh Options Ideas

STZ Weekly $225-230 Calls
BBBY Weekly $20-19 Puts
WBA Weekly $43.50-44 Calls


CURR NEWS: 

OXNARD, Calif.–(BUSINESS WIRE)– CURE Pharmaceutical Holding Corp (“CURE” or the “Company”) (OTC: CURR), a technology-focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space, announced today that the Company’s Chief Executive Officer Rob Davidson will be presenting at the H.C. Wainwright BioConnect 2021 Virtual Conference being held January 11-14. The presentation can be viewed beginning at 6:00 a.m. EST on January 11, 2021, and can be accessed here through registration and will be available online until January 14. (>>View Full PR)


Extended Watchlist: 
ALYI, BLSP, KSHB, LRDC, INTV

Bitcoin Options Really Popping

Bitcoin Options Review

At the beginning of last week, we began to pay much closer attention to bitcoin related plays as the digital currency was passing $28K and heading to new highs. We started by tracking the MARA 01/15 $13-15 Calls that morning, and added more targets to the mix this Monday morning in the form of the MARA Weekly $11-12 Calls and the RIOT Weekly $17-19 Calls. In the case of the latter two, they were our first fresh options ideas of the new trading year, so it’s nice to hit on those.

With Bitcoin surging to new all time highs once again, now trading between $34K and $35K we expect to have to come back yet again and report even further gains, but as of yesterday’s close, here were the excellent gains we had witnessed so far: 

RIOT Weekly $17-19 Calls 
$17: .65-2.24 (+245%)
$18: .52-1.67 (+221%)
$19: .35-1.19 (+240%)
______

MARA Weekly $11-12 Calls
$11: 1.32-3.90 (+195%)
$12: 1.06-3.25 (+207%)
______

MARA 01/15 $13-15 Calls
$13
: .80-2.72 (+240%)
$14: .62-2.30 (+270%)
$15: .50-1.95 (+290%)


Extended Watchlist: 
BLPG, LCLP, CBDL, TPII, USRM, VIBI

CURR News Update & More

CURE Pharmaceutical Holding Corp. (OTCMKTS:CURR)

We’re looking back in on CURR this morning on the heels of a key PR released by the company that we would like to share with our readers. We have been following this stock for roughly a month, and this FDA IND approval news is by far the most exciting development yet.

CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space, announced today that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for its product CUREfilm Blue™, an oral soluble film of sildenafil citrate (the active ingredient present in Viagra®1) for the treatment of erectile dysfunction (ED). CURE is seeking approval of this product via the 505(b)(2) regulatory pathway to expedite the U.S. approval process. (>>View Full PR via OTCMARKETS)

In addition to familiarizing yourself with the company’s news update, we would recommend you take a couple of minutes to check out the video presentation of the CURR chart that we have provided below: 


______

Please direct any investor inquiries on CURR to:

Gary Zwetchkenbaum
Plum Tree Consulting LLC
Phone: (718) 224-3123
Cell: (516) 455-7662
Website: www.plumtreeconsultingllc.com


Fresh Options Ideas:
SPY 01/06 $368-367 Puts


Extended Watchlist: 
TSPG, WDLF, ISWH, USRM, OZSC, LBRMF